Founded in 1997, Chengdu Rongsheng is a core subsidiary of BTBP. In 2001, Chengdu Institute of Biological Products Co., Ltd has transferred its blood product business to Chengdu Rongsheng. In the early 1980s, Chengdu Rongsheng established the first batch of plasmapheresis centers nationwide. With rich experience in source plasma management, Chengdu Rongsheng was the first to start industrial production of blood products in China, securing numerous firsts in the domestic blood product industry. In 2008, it has been recognized as a high-tech enterprise; In 2019, it was awarded the title of "Sichuan Province Brand Value Benchmark Enterprise".

The "Rongsheng" brand blood product have dominated the Chinese blood product market with its comprehensive advantages in quality, safety, market share, and brand value for decades. It has also been praised by the Ministry of Health as a "model of blood products". The market sales of "Rongsheng" IVIG have ranked first in the country for consecutive years, and the cumulative clinical use of "Rongsheng" human albumin has exceeded 23 million times.

Lanzhou Plasma, originated from the Blood Products Department of Lanzhou Institute of Biological Products Co., Ltd, is one of the very first group of blood product manufacturers in China. As early as 1996, it introduced low-temperature ethanol pressure filtration technology from Switzerland into China for the first time, and accumulated profound technical experience in the field of blood product manufacturing ever since. In 2022, it was renamed as "Sinopharm Lanzhou Biopharmaceuticals Co., Ltd".

As a major supplier of blood products in the northwest China, its products have been selected as "Famous Brand Products in Gansu Province" multiple times. Its human albumin and intravenous immunoglobulin were selected for the Gansu Brand Cultivation Catalogue in 2021. In 2019, Lanzhou Plasma was recognized as a high-tech enterprise; In 2021, it was rated as a "Specialized, Refined, Unique, and Innovative" enterprise in Gansu Province; In 2022, it was awarded the title of "Advanced Enterprise in Gansu Province" by the Gansu Provincial Party Committee and Government, and the title of "User Satisfied Enterprise in Gansu Province" by the Gansu Provincial Quality Association, and was rated AA for its market quality credit.

Shanghai Plamsa was originated from the biopharmaceutical business of Shanghai Institute of Biological Products Co., Ltd. Located in 350 Anshun Road, Changning District, Shanghai, Shanghai Plasma has a long history of blood product manufacturing. In the 1960s, Shanghai Plamsa was the first in China to use low-temperature ethanol plasma protein separation technology to manufacture human albumin and human immunoglobulin; In 1991, a modern blood product production line was introduced into China from Japan by Shanghai Plamsa, which has became the most invested, largest production scale, and most advanced technological transformation project in the history of biological product industry of China. The production line was also one of the largest in Asia at that time; In 1998, it passed the national GMP certification, which was one of the earliest in China; In 2019, it was recognized as a high-tech enterprise.

In 2022,  Shanghai Plasma established Sinopharm Kunming Plasma-derived Biotherapies Co., Ltd(referred to as "Kunming Plasma") in the manner of split-off. Kunming Plasma is located at No. 3696 Zhongning Road, Dianzhong New Area, Yunnan Province, with a designed annual plasma fractionation capacity of over 1200 tons and an estimated total investment of 2.7 billion yuan. While serving the market demand of Yunnan Province, Kunming Plasma aims to build a high-end biopharmaceutical manufacturing center for South Asia and Southeast Asia. In 2022, it has built an internationally leading and domestically first-class intelligent manufacturing factory for blood product manufacturing. Once in formal operation, it will become one of the largest blood product research and production bases in Asia.

Wuhan Plasma was originated from the biopharmaceutical business of Wuhan Institute of Biological Products Co., Ltd. It owns an advanced plasma protein separation workshop and was one of the firsts in China to pass the 2010 version of GMP certification. It has established an effective quality assurance system and was recognized as a high-tech enterprise in 2018. In 2023, it was renamed as " Sinopharm Wuhan Biopharmaceuticals Co., Ltd".

Wuhan Plasma always takes quality as the lifeline of the enterprise. It has established a comprehensive management system to continuously improve the products quality. In 2018, Wuhan Plasma was awarded the title of "Little Giant" in Wuhan's science and technology industry; In 2021, it successfully passed the recognition of the "Hubei Enterprise Technology Center" and the "Little Giant" of Hubei Province, and was awarded the honorary title of "Labor Medal" by the Hubei Federation of Trade Unions.

Guizhou Plasma is a high-tech enterprise that integrates the production, learning, research, and sales of blood products. Its predecessor was the Jinan Military Region Institute of Biological Products, which was restructured as Henan Zhongtai Pharmaceutical Co., Ltd. in 2001. In 2006, Henan Zzhongtai has renamed as Guizhou Zhongtai Biotechnology Co., Ltd, and registered in the Guizhou Southeast High-tech Development Zone through key investment attraction. In 2015, it joined CNBG, and in 2017, it has been integrated into BTBP. In 2018, it was recognized as a high-tech enterprise and in 2024, it was renamed as "Sinopharm Guizhou Biopharmaceuticals Co., Ltd".

Guizhou Plasma is one of the earliest enterprises in China to manufacture blood products. It shoulders the responsibility of providing high-quality blood products for clinical use. The registered trademark "Guardian" of the company is a famous trademark in Guizhou Province, and its products have won the title of "Famous Brand Product in Guizhou Province" multiple times, with a good market reputation.

Xi'an Plasma, formerly known as Xi'an Huitian Blood Products Co., Ltd, was established in October 1996 as one of the first national designated blood product manufacturing enterprise and also the first biopharmaceutical enterprise  to pass GMP certification in Shaanxi Province. Its annual plasma fractionation capacity reaches 400 tons. Its human albumin and intravenous immunoglobulin products have been listed as recommended products for the European Union market by the French Technical Quality Supervision and Evaluation Committee, and also boast high popularity and market influence in the northwest of China, Shandong provinces, Henan province and other regions.

In August 2022, BTBP completed the acquisition of Xi'an Huitian and renamed it as "Sinopharm Xi'an Biopharmaceuticals Co., Ltd".